Dr. Mahvash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Armeen Mahvash is a radiologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Baylor College of Medicine and has been in practice 18 years. He specializes in vascular & interventional radiology.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Vascular and Interventional Radiology, 2005 - 2006
- University of Texas Health Science Center at HoustonResidency, Radiology-Diagnostic, 2000 - 2004
- John Peter Smith Hospital (Tarrant County Hospital District)Internship, Transitional Year, 1999 - 2000
- Baylor College of MedicineClass of 1999
Certifications & Licensure
- TX State Medical License 2004 - 2024
- American Board of Radiology Interventional Radiology and Diagnostic Radiology
Clinical Trials
- Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma Start of enrollment: 2010 Aug 04
- Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Start of enrollment: 2012 Jan 01
- Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer Start of enrollment: 2017 Jan 09
- Join now to see all
Publications & Presentations
PubMed
- Unlocking Precision in Radioembolization: Navigating the Future of Holmium-166 Radioembolization Mapping and Lung Shunt Study by Implementing Scout Dosimetry.Peiman Habibollahi, Armeen Mahvash, Nima Kokabi, Nariman Nezami> ;Cardiovascular and Interventional Radiology. 2024 Mar 15
- Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features.Tran Cao, H., Witt, R., Elsayes, K., Baiomy, A., Xiao, L., Palmquist, S., Lee, S., Mohamed, Y., Mahvash, A., Tzeng, C., Chun, Y., Koay, E., Rashid, A., Hassan, M., Yao...> ;The Oncologist. 2023 Dec 30
- 1 citationsDirect comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatoce...Marnix Lam, Etienne Garin, Xavier Palard-Novello, Armeen Mahvash, Cheenu Kappadath, Paul Haste, Mark Tann, Ken Herrmann, Francesco Barbato, Brian Geller, Niklaus Schae...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2023 Dec 1
- Join now to see all
Press Mentions
- Sirtex Commences DOORwaY-90 Study for SIR-Spheres Therapy as First-Line Treatment of Unresectable HCCMay 10th, 2021
- Sirtex Medical Announces New SIR-Spheres(R) DOORwaY-90 Study: The First Prospective Multicenter U.S.-based Trial for Registration as First-Line Treatment for Hepatocellular CarcinomaMarch 22nd, 2021
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: